Multimmune GmbH

• Short facts

• • Research & Development
• Year founded 1999
• 6 Employees (site)
• Turnover: <5m EUR

Products/services: multimmune GmbH is a private biopharmaceutical company focused on the development of innovative therapeutics for cancers that express heat shock protein 70 (Hsp70). The Company has developed a unique and proprietary technology platform based on the discovery that cell surface-bound Hsp70 is expressed on many tumor types but not on healthy cells. The Company is currently developing four patent-protected approaches for therapeutic intervention and companion diagnostics using this technology platform: 1. Activation of Natural Killer (NK) cells using a synthetic peptide that mimics Hsp70 (ENKASTIM-ev, End-Phase I product) 2. An antibody against Hsp70 (mi-TUMEX, Preclinical product) 3. Immune stimulation via Hsp70 peptide (ENKASTIM-iv, Preclinical product) 4. Tumor-specific apoptosis via Hsp70 and Granzyme B (mi-APO, Preclinical product). multimmune GmbH was established in 1999 and is based in Munich (Germany) within easy reach of international airports. The Company has been financed by private investors and respected venture capital firms, including S-Refit AG, Bayern Kapital and tbg. multimmune GmbH is a private biopharmaceutical company focused on the development of innovative therapeutics for cancers that express heat shock protein 70 (Hsp70). The Company has developed a unique and proprietary technology platform based on the discovery that cell surface-bound Hsp70 is expressed on many tumor types but not on healthy cells. The Company is currently developing four patent-protected approaches for therapeutic intervention and companion diagnostics using this technology platform: 1. Activation of Natural Killer (NK) cells using a synthetic peptide that mimics Hsp70 (ENKASTIM-ev, End-Phase I product) 2. An… read more